NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy cenegermin on the NHS for the treatment of the rare eye condition neurotrophic keratitis.
Ook interessant voor je
NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy cenegermin on the NHS for the treatment of the rare eye condition neurotrophic keratitis.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
Reageer